Skip to main content

Nixon Peabody LLP

  • People
  • Capabilities
  • Insights
  • About
Trending Topics
    • People
    • Capabilities
    • Insights
    • About
    • Locations
    • Events
    • Careers
    • Alumni
    Practices

    View All

    • Affordable Housing
    • Community Development Finance
    • Corporate & Finance
    • Cybersecurity & Privacy
    • Entertainment & Media
    • Environmental
    • Franchising & Distribution
    • Government Investigations & White Collar Defense
    • Healthcare
    • Intellectual Property
    • International Services
    • Labor, Employment, and Benefits
    • Litigation
    • Private Wealth & Advisory
    • Project Finance
    • Public Finance
    • Real Estate
    • Regulatory & Government Relations
    Industries

    View All

    • Aviation
    • Cannabis
    • Consumer
    • Energy
    • Financial Services
    • Healthcare
    • Higher Education
    • Infrastructure
    • Manufacturing
    • Nonprofit Organizations
    • Real Estate
    • Sports & Stadiums
    • Technology
    Value-Added Services

    View All

    • Alternative Fee Arrangements

      Developing innovative pricing structures and alternative fee agreement models that deliver additional value for our clients.

    • Continuing Education

      Advancing professional knowledge and offering credits for attorneys, staff and other professionals.

    • Crisis Advisory

      Helping clients respond correctly when a crisis occurs.

    • DEI Strategic Services

      Providing our clients with legal, strategic, and practical advice to make transformational changes in their organizations.

    • eDiscovery

      Leveraging law and technology to deliver sound solutions.

    • Environmental, Social, and Governance (ESG)

      We help clients create positive return on investments in people, products, and the planet.

    • Global Services

      Delivering seamless service through partnerships across the globe.

    • Innovation

      Leveraging leading-edge technology to guide change and create seamless, collaborative experiences for clients and attorneys.

    • IPED

      Industry-leading conferences focused on affordable housing, tax credits, and more.

    • Legal Project Management

      Providing actionable information to support strategic decision-making.

    • Legally Green

      Teaming with clients to advance sustainable projects, mitigate the effects of climate change, and protect our planet.

    • Nixon Peabody Trust Company

      Offering a range of investment management and fiduciary services.

    • NP Capital Connector

      Bringing together companies and investors for tomorrow’s new deals.

    • NP Second Opinion

      Offering fresh insights on cases that are delayed, over budget, or off-target from the desired resolution.

    • NP Trial

      Courtroom-ready lawyers who can resolve disputes early on clients’ terms or prevail at trial before a judge or jury.

    • Social Impact

      Creating positive impact in our communities through increasing equity, access, and opportunity.

    • Women in Dealmaking

      We provide strategic counsel on complex corporate transactions and unite dynamic women in the dealmaking arena.

    1. Home
    2. Insights
    3. Alerts
    4. New House committee on coronavirus may shift investigatory landscape for federal fund recipients

      Alerts

    Alert / Congressional Investigations

    New House committee on coronavirus may shift investigatory landscape for federal fund recipients

    May 1, 2020

    LinkedInX (Twitter)EmailCopy URL

    By J. William Codinha, Gordon Lang, Adam Tarosky and Ronaldo Rauseo-Ricupero

    The U.S. House of Representatives’ new Select Subcommittee on the Coronavirus Crisis has the potential to shift the center of public oversight activity from the Treasury Department to Congress.

    DOWNLOAD

    House coronavirus committee may shift investigatory landscape (PDF)

    With Congress continuing to pass additional stimulus to supplement the more than $2 trillion under the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”), the U.S. House of Representatives’ new Select Subcommittee on the Coronavirus Crisis has the potential to shift the center of public oversight activity from the Treasury Department to Congress.

    Created on April 23 by the House’s passage of a bill sponsored by House Rules Committee Chairman Jim McGovern (D-MA), this subcommittee of the Oversight and Reform Committee is chaired by Minority Whip James Clyburn (D-S.C.), enjoys the power to subpoena documents and depose witnesses, and will start with a $2M budget to undertake its work.

    This Committee’s creation suggests that a number of CARES Act fund recipients may be facing their most visible oversight from a congressional inquiry rather than from an agency enforcement proceeding. Speaker Pelosi explained that the panel’s goal is to ensure that the funds that “Congress has dedicated to this battle—and any additional funds Congress provides in future legislation—are spent wisely and effectively.” The subcommittee is intended to follow the mold of the World War II-era Truman Committee, which investigated profiteering, price gouging, and other abuses related to government defense funding. It will be comprised of seven Democrats, including three chairs of existing House committees: Oversight Committee Chair Carolyn Maloney (D-NY), Financial Services Committee Chair Maxine Waters (D-CA), Small Business Committee Chair Nydia Velazquez (D-NY), and Reps. Jamie Raskin (D-MD), Bill Foster (D-IL), and Andy Kim (D-NJ), as well as up to five Republicans who have not yet been named.

    As outlined in a previous alert, businesses receiving funds through the CARES Act will be facing careful oversight scrutiny built into the legislation, including through the new office of Special Inspector General for Pandemic Recovery (SIGPR), which is tasked with conducting, supervising, and coordinating audits and investigations of the making, purchase, management, and sale of loans, loan guarantees, and other investments made under the Cares Act and which is required to file quarterly reports with Congress that provide the details of all loans, loan guarantees, and other investments. The legislation has provided $25M for the SIGPR to perform its work.

    The CARES Act also provides for oversight to reside in three other entities:

    • The Pandemic Response Accountability Committee. This panel of two dozen federal inspectors general charged with coordinating work to investigate the coronavirus relief effort is a committee of the Council of the Inspectors General on Integrity and Efficiency (CIGIE), an independent entity established within the executive branch.
    • The COVID-19 Congressional Oversight Commission. This five-person panel is responsible for conducting oversight of the Treasury Department, the Federal Reserve, and the agencies’ implementation of the CARES Act. The members, Sen. Pat Toomey (R-PA), Bharat Ramamurti (D), Rep. Donna Shalala (D-FL), and Rep. French Hill (R-AR) have been named by the Senate Majority and Minority Leaders and the House Speaker and Minority Leader respectively. The Speaker and Senate Majority Leader will jointly select the chair.
    • The U.S. Government Accountability Office (GAO). The CARES Act provides $20M for this legislative branch agency to conduct oversight of the programs covered by the CARES Act. It will issue a report on its oversight of CARES Act spending 90 days after enactment and issue bi-monthly reports through the first year. GAO has already begun focusing on “the testing for the virus, the availability of personal protective equipment as well as infection control at nursing homes.”

    It is yet to be seen how the new House Select Subcommittee will undertake its charge in light of social distancing. One method recently employed by the Senate Commerce Committee is a “paper hearing” in which opening statements and testimony were submitted and posted on the committee’s website and witnesses were asked to submit written answers to members’ questions within 96 business hours. Subjects of oversight should be prepared for responding to such non-traditional requests in light of the current public health protocols.

    Regardless of how congressional investigators proceed, CARES Act funding recipients can take a number of steps now to help position themselves well to respond if such inquiries follow:

    • Continually reconfirm accuracy of financial records; care should be taken to have independently audited financials. If amendments or corrections to submissions to the government are contemplated, counsel should be consulted to assess potential impacts.
    • Carefully vet communications with granting agencies or lenders; any representation or certification to a government agency (whether on a conference call, in an email, or a Zoom meeting) can give rise to a False Claims Act violation allegation if not truthful. Potential inconsistencies with any prior applications or submissions should be carefully investigated before the representation or certification is conveyed to an agency.
    • Segregate and track the use of CARES Act funding in separate accounts, and ensure staff and compliance personnel are well versed in permissible uses of such funds. Identify an individual charged with routinely and periodically assuring compliance.
    • Enhance overall compliance operations; documenting efforts to step up internal watchdog functions, including vigorous responses to anonymous complaints, will be key in demonstrating a culture of responsiveness and special diligence around CARES Act funds.
    • Review and update document preservation policies and procedures in light of specific CARES Act requirements; most forms of relief obligate recipients to retain certain records, such as those that support any statement in an application, certification, or agreement for specified periods that may exceed routine document destruction practices.
    • Demonstrate progress on a plan to achieve repayment by carefully documenting hires, costs, and other business expenses, which can underline a business’ determination to qualify for forgiveness or repayment from the outset.

    CARES Act funding recipients may receive inquiries from any of these congressional or agency oversight authorities, and response strategies will vary substantially. Nixon Peabody’s experienced Congressional Investigations Team is prepared to advise clients in handling such requests.

    Practices

    Affordable HousingCommunity Development FinanceFinancial Restructuring & BankruptcyFranchising & DistributionMergers, Acquisitions, and Corporate Transactions Private Equity & Investment FundsGovernment Investigations & White Collar DefenseCongressional InvestigationsFalse Claims Act & Qui Tam MattersHealthcareComplex DisputesAntitrustConstruction & Real Estate Litigation

    Industries

    Food, Beverage & AgribusinessBanking & FinanceHealthcare

    Insights And Happenings

    • Alert

      Navigating shareholder and government scrutiny of COVID-19 product claims

      Aug 27, 2020
    • Alert

      CMS announces enhanced enforcement actions for nursing homes and publishes data on long-term care facilities with coronavirus (COVID-19) cases

      June 5, 2020
    • Alert

      First PPP fraud prosecution provides preview of government scrutiny for which all CARES Act beneficiaries must prepare

      May 8, 2020
    The foregoing has been prepared for the general information of clients and friends of the firm. It is not meant to provide legal advice with respect to any specific matter and should not be acted upon without professional counsel. If you have any questions or require any further information regarding these or other related matters, please contact your regular Nixon Peabody LLP representative. This material may be considered advertising under certain rules of professional conduct.

    Subscribe to stay informed of the latest legal news, alerts, and business trends.Subscribe

    • People
    • Capabilities
    • Insights
    • About
    • Locations
    • Events
    • Careers
    • Alumni
    • Cookie Preferences
    • Privacy Policy
    • Terms of Use
    • Accessibility Statement
    • Statement of Client Rights
    • Purchase Order Terms & Conditions
    • Nixon Peabody International LLC
    • PAL
    © 2025 Nixon Peabody. All rights reserved